COUNTERING COUNTERFEITS
Industry offers proposals to fight growing problem of fake drugs.

BAYER CHEMICALS TO TAKE A SPIN
Split-off of chemicals will shift firm�s focus to life sciences

BIOTECH SCORES BIG THIRD-QUARTER GAINS
Substantial revenue and earnings growth continued unabated for yet another quarter

DRUG EARNINGS RALLY IN THE THIRD QUARTER
Major pharmaceutical firms see improvement in sales and earnings as the year progresses

It Lives for 29 Years?
A lawsuit filed April 11 in the U.S. District Court in Los Angeles has grabbed the attention of the life sciences community. The key parties are three high-profile biotech developers: MedImmune, Genentech and Celltech. MedImmune is challenging the validity and enforceability of an important Genentech patent. Behind that patent, MedImmune charges, is an illegal, anti-competitive agreement that ‘profoundly and fundamentally altered the competitive landscape in the biotechnology industry.’

Big pharma plays hard ball with little biotech
If you play with the big boys you might get hurt…

USDA Sued Over Drug-Growing Crops
A coalition of environmental groups and consumer advocates sued the U.S. Agriculture Department in federal court on Wednesday to try to halt the experimental planting of biotech crops engineered to make medicine.

Staffing needs seen in biotech industry
A top Labor Department official said yesterday that community colleges nationwide could boost their courses in the life sciences next year as part of an effort to meet the staffing needs of the biotechnology industry.

Getting Investors’ Pulses Beating Again
Any biotech slowdown will be temporary, says VC Nick Galakatos, who believes 2004′s ‘promising products’ will be a catalyst for the sector

Financial Snapshot For October 2003
Stocks On New Plateau